Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 10/10

vs
industry
vs
history
Cash to Debt No Debt
GLYC's Cash to Debt is ranked higher than
74% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: 46.43 vs. GLYC: No Debt )
Ranked among companies with meaningful Cash to Debt only.
GLYC' s Cash to Debt Range Over the Past 10 Years
Min: N/A  Med: No Debt Max: No Debt
Current: No Debt
N/A
No Debt
Equity to Asset 0.87
GLYC's Equity to Asset is ranked higher than
78% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. GLYC: 0.87 )
Ranked among companies with meaningful Equity to Asset only.
GLYC' s Equity to Asset Range Over the Past 10 Years
Min: 0.55  Med: 0.84 Max: 0.95
Current: 0.87
0.55
0.95
Interest Coverage No Debt
GLYC's Interest Coverage is ranked higher than
66% of the 458 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. GLYC: No Debt )
Ranked among companies with meaningful Interest Coverage only.
GLYC' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
F-Score: 3
Z-Score: 8.91
M-Score: 195174.04
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -60079.63
GLYC's Operating margin (%) is ranked lower than
98% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -78.20 vs. GLYC: -60079.63 )
Ranked among companies with meaningful Operating margin (%) only.
GLYC' s Operating margin (%) Range Over the Past 10 Years
Min: -60079.63  Med: -74.13 Max: 23.83
Current: -60079.63
-60079.63
23.83
Net-margin (%) -59933.33
GLYC's Net-margin (%) is ranked lower than
98% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -75.28 vs. GLYC: -59933.33 )
Ranked among companies with meaningful Net-margin (%) only.
GLYC' s Net-margin (%) Range Over the Past 10 Years
Min: -59933.33  Med: -74.01 Max: 23.96
Current: -59933.33
-59933.33
23.96
ROE (%) -75.41
GLYC's ROE (%) is ranked lower than
73% of the 878 Companies
in the Global Biotechnology industry.

( Industry Median: -33.45 vs. GLYC: -75.41 )
Ranked among companies with meaningful ROE (%) only.
GLYC' s ROE (%) Range Over the Past 10 Years
Min: -137.43  Med: -41.42 Max: 34.84
Current: -75.41
-137.43
34.84
ROA (%) -65.07
GLYC's ROA (%) is ranked lower than
77% of the 971 Companies
in the Global Biotechnology industry.

( Industry Median: -29.51 vs. GLYC: -65.07 )
Ranked among companies with meaningful ROA (%) only.
GLYC' s ROA (%) Range Over the Past 10 Years
Min: -89.49  Med: -24.15 Max: 15.45
Current: -65.07
-89.49
15.45
ROC (Joel Greenblatt) (%) -5911.63
GLYC's ROC (Joel Greenblatt) (%) is ranked lower than
82% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: -372.06 vs. GLYC: -5911.63 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
GLYC' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -5911.63  Med: -1944.15 Max: 1059.77
Current: -5911.63
-5911.63
1059.77
» GLYC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

GLYC Guru Trades in Q4 2015

Jim Simons 60,921 sh (+27.45%)
» More
Q1 2016

GLYC Guru Trades in Q1 2016

Jim Simons 69,200 sh (+13.59%)
» More
Q2 2016

GLYC Guru Trades in Q2 2016

Paul Tudor Jones 55,000 sh (New)
Jim Simons 114,600 sh (+65.61%)
» More
Q3 2016

GLYC Guru Trades in Q3 2016

Jim Simons 134,100 sh (+17.02%)
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with GLYC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:ATHX, OTCPK:PAIOF, AMEX:NAVB, OTCPK:SPRWF, NAS:RDHL, NAS:NYMX, NAS:VVUS, NAS:XENE, NAS:ABUS, NAS:RGLS, NAS:ITEK, NAS:ENZY, NAS:AKAO, OTCPK:CTIX, NAS:AXSM, NAS:NVIV, NAS:AVXL, NAS:CASC, OTCPK:OGRMF, NAS:IMGN » details
Traded in other countries:GKO.Germany,
GlycoMimetics Inc is a clinical stage biotechnology company. The Company is engaged in discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role.

Ratios

vs
industry
vs
history
Forward P/E 5.25
GLYC's Forward P/E is ranked higher than
95% of the 55 Companies
in the Global Biotechnology industry.

( Industry Median: 17.39 vs. GLYC: 5.25 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 3.23
GLYC's P/B is ranked higher than
52% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: 3.50 vs. GLYC: 3.23 )
Ranked among companies with meaningful P/B only.
GLYC' s P/B Range Over the Past 10 Years
Min: 1.81  Med: 2.91 Max: 5.3
Current: 3.23
1.81
5.3
P/S 1938.19
GLYC's P/S is ranked lower than
98% of the 695 Companies
in the Global Biotechnology industry.

( Industry Median: 10.41 vs. GLYC: 1938.19 )
Ranked among companies with meaningful P/S only.
GLYC' s P/S Range Over the Past 10 Years
Min: 3.94  Med: 10.39 Max: 4485
Current: 1938.19
3.94
4485
Current Ratio 8.59
GLYC's Current Ratio is ranked higher than
72% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. GLYC: 8.59 )
Ranked among companies with meaningful Current Ratio only.
GLYC' s Current Ratio Range Over the Past 10 Years
Min: 2.14  Med: 8.59 Max: 21.83
Current: 8.59
2.14
21.83
Quick Ratio 8.59
GLYC's Quick Ratio is ranked higher than
73% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.94 vs. GLYC: 8.59 )
Ranked among companies with meaningful Quick Ratio only.
GLYC' s Quick Ratio Range Over the Past 10 Years
Min: 2.14  Med: 8.59 Max: 21.83
Current: 8.59
2.14
21.83
Days Sales Outstanding 3.00
GLYC's Days Sales Outstanding is ranked higher than
93% of the 601 Companies
in the Global Biotechnology industry.

( Industry Median: 61.72 vs. GLYC: 3.00 )
Ranked among companies with meaningful Days Sales Outstanding only.
GLYC' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.53  Med: 0.62 Max: 3
Current: 3
0.53
3

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.51
GLYC's Price/Net Cash is ranked higher than
69% of the 518 Companies
in the Global Biotechnology industry.

( Industry Median: 6.05 vs. GLYC: 3.51 )
Ranked among companies with meaningful Price/Net Cash only.
GLYC' s Price/Net Cash Range Over the Past 10 Years
Min: 2.29  Med: 3.49 Max: 5.59
Current: 3.51
2.29
5.59
Price/Net Current Asset Value 3.39
GLYC's Price/Net Current Asset Value is ranked higher than
70% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 5.53 vs. GLYC: 3.39 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
GLYC' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.25  Med: 2.8 Max: 5.54
Current: 3.39
2.25
5.54
Price/Tangible Book 3.28
GLYC's Price/Tangible Book is ranked higher than
61% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. GLYC: 3.28 )
Ranked among companies with meaningful Price/Tangible Book only.
GLYC' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.19  Med: 2.74 Max: 5.49
Current: 3.28
2.19
5.49
Price/Median PS Value 198.00
GLYC's Price/Median PS Value is ranked lower than
99% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 0.93 vs. GLYC: 198.00 )
Ranked among companies with meaningful Price/Median PS Value only.
GLYC' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.55  Med: 0.94 Max: 363.5
Current: 198
0.55
363.5
Earnings Yield (Greenblatt) (%) -35.91
GLYC's Earnings Yield (Greenblatt) (%) is ranked lower than
80% of the 942 Companies
in the Global Biotechnology industry.

( Industry Median: -8.50 vs. GLYC: -35.91 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
GLYC' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -57.31  Med: 0 Max: 0
Current: -35.91
-57.31
0

More Statistics

Revenue (TTM) (Mil) $0.05
EPS (TTM) $ -1.62
Short Percentage of Float11.37%
52-Week Range $3.70 - 9.25
Shares Outstanding (Mil)23.07

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 60 50 41
EPS ($) -1.54 1.18 0.62 0.09
EPS w/o NRI ($) -1.54 1.18 0.62 0.09
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for GLYC

Headlines

Articles On GuruFocus.com

More From Other Websites
GlycoMimetics' GMI-1271 Continues to Yield High Remission Rates, Favorable Tolerability in Two Phase... Dec 05 2016
GLYCOMIMETICS INC Financials Nov 11 2016
GlycoMimetics to Present at Upcoming Healthcare Investor Conferences Nov 10 2016
GlycoMimetics to Present at Upcoming Healthcare Investor Conferences Nov 10 2016
GlycoMimetics to Present at Upcoming Healthcare Investor Conferences Nov 10 2016
GlycoMimetics to Present Preclinical Cancer Results at Society for Immunotherapy of Cancer Meeting Nov 08 2016
GlycoMimetics Reports Third Quarter 2016 Results and Progress in Clinical Development Nov 04 2016
GLYCOMIMETICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Nov 04 2016
GlycoMimetics reports 3Q loss Nov 04 2016
GlycoMimetics reports 3Q loss Nov 04 2016
GlycoMimetics Reports Third Quarter 2016 Results and Progress in Clinical Development Nov 04 2016
GLYCOMIMETICS INC Files SEC form 10-Q, Quarterly Report Nov 04 2016
Data from Three GlycoMimetics Drug Candidates to Be Highlighted at 58th Annual American Society of... Nov 03 2016
GLYCOMIMETICS INC Files SEC form 8-K, Change in Directors or Principal Officers Sep 23 2016
GlycoMimetics Doses First Patient in Phase 1 Clinical Trial of Drug Candidate GMI-1271 for Multiple... Sep 14 2016
GlycoMimetics Doses First Patient in Phase 1 Clinical Trial of Drug Candidate GMI-1271 for Multiple... Sep 14 2016
Glycomimetics Joins New Sickle Cell Disease Coalition, Issues Call to Action to Improve Treatment... Sep 09 2016
GlycoMimetics Initiates Dosing in Phase 1 Clinical Trial of GMI-1359 Sep 06 2016
GlycoMimetics Initiates Dosing in Phase 1 Clinical Trial of GMI-1359 Sep 06 2016
GlycoMimetics Announces Publication of Preclinical Data Showing Drug Candidate GMI-1271 Reduces... Aug 16 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)